Use of a plasminogen activating factor (A) for treatment of stroke, where the activity of (A) is increased by more than 650 fold in presence of fibrin, is new. Independent claims are also included for the following: (1) tissue plasminogen activator (tPA) having an autolysis loop that includes His420, Asn421, Ala422 and Cys423 (2) urokinase having an autolysis loop that includes Val420, Thr421, Asp422 and Ser423 and (3) pharmaceutical composition containing (A) and at least one other medically active agent, or their salts. ACTIVITY : Cerebroprotective. No biological data is given. MECHANISM OF ACTION : None given.